The Effect of Oral Contraceptive Different Patterns of Use on Circulating IGF-1 and Bone Mineral Density in Healthy Premenopausal Women

Overview

Journal Endocrine

Specialty Endocrinology

Date 2014 May 28

PMID 24861474

Citations 7

Authors

Amany Y Elkazaz

Khaled Salama

Affiliations

Soon will be listed here.

Abstract

Both insulin-like growth factor-1(IGF-1) and oral contraceptive (OC) use have been linked to premenopausal breast and colorectal cancers, osteoporosis and cardiovascular disease. Understanding the effects of different patterns of use of OC on IGF-1 levels and bone mineral density (BMD) may offer insight into its influence on osteoporosis. We conducted a cross-sectional study, which included 135 women, who were then divided into three groups: Group A who were OC current users, 41 women; Group B who never use OC, 51 women; and Group C who were past users of OC, 41 women. Each patient completed a questionnaire on demographic parameters, marital state history and contraception history including duration of use and type of contraceptive pills or used method. Lower-end radius, proximal femur and lumbar spine BMD were measured by dual-energy X-ray absorptiometry. IGF-1 was assessed with chemiluminescent immunometric assay. The three groups were similar in total body T value of BMD (with slight better results in past users than the other two groups but it was statistically insignificant difference), and past users showed significantly higher BMD values compared to current users at spine, femur and forearm. Nonusers also had better BMD values compared to current users (spine and forearm BMD). Among past users, the mean level of circulating IGF-1 was higher than the other two groups and that difference was statistically significant. Past OC use and/or nonuse has a more favorable impact on BMD compared to current use and that this relationship is in part mediated by IGF-1. Hence, it appears that OC use is beneficial to BMD if used in the past and then discontinued or if never used at all compared to current use.

Citing Articles

Hormonal and non-hormonal oral contraceptives given long-term to pubertal rats differently affect bone mass, quality and metabolism.

Porwal K, Sharma S, Kumar S, Tomar M, Sadhukhan S, Rajput S Front Endocrinol (Lausanne). 2023; 14:1233613.

PMID: 37664835 PMC: 10470083. DOI: 10.3389/fendo.2023.1233613.

Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS.

Shah A, Dodson W, Kris-Etherton P, Kunselman A, Stetter C, Gnatuk C J Clin Endocrinol Metab. 2020; 106(1):108-119.

PMID: 32968804 PMC: 7765645. DOI: 10.1210/clinem/dgaa682.

Are the Effects of Oral and Vaginal Contraceptives on Bone Formation in Young Women Mediated via the Growth Hormone-IGF-I Axis?.

Allaway H, Misra M, Southmayd E, Stone M, Weaver C, Petkus D Front Endocrinol (Lausanne). 2020; 11:334.

PMID: 32612574 PMC: 7309348. DOI: 10.3389/fendo.2020.00334.

Oral contraceptive use, bone mineral density, and bone turnover markers over 12 months in college-aged females.

Almstedt H, Cook M, Bramble L, Dabir D, LaBrie J J Bone Miner Metab. 2020; 38(4):544-554.

PMID: 31983034 PMC: 10317246. DOI: 10.1007/s00774-019-01081-1.

Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews.

Blanchet C, Guillaume S, Bat-Pitault F, Carles M, Clarke J, Dodin V J Clin Med. 2019; 8(2).

PMID: 30823566 PMC: 6406645. DOI: 10.3390/jcm8020278.

References

Balogh A, Kauf E, Vollanth R, Graser G, Klinger G, Oettel M . Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH). Contraception. 2001; 62(5):259-69. DOI: 10.1016/s0010-7824(00)00176-1. View

Gullberg B, Johnell O, Kanis J . World-wide projections for hip fracture. Osteoporos Int. 1997; 7(5):407-13. DOI: 10.1007/pl00004148. View

Goldspink G . Loss of muscle strength during aging studied at the gene level. Rejuvenation Res. 2007; 10(3):397-405. DOI: 10.1089/rej.2007.0597. View

Allen N, Appleby P, Kaaks R, Rinaldi S, Davey G, Key T . Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control. 2003; 14(1):65-74. DOI: 10.1023/a:1022518321634. View

Allali F, El Mansouri L, Abourazzak F, Ichchou L, Khazzani H, Bennani L . The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women. BMC Womens Health. 2009; 9:31. PMC: 2776575. DOI: 10.1186/1472-6874-9-31. View

Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N . Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2001; 10(4):377-84. View

Michaelsson K, Baron J, Farahmand B, Persson I, Ljunghall S . Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet. 1999; 353(9163):1481-4. DOI: 10.1016/S0140-6736(98)09044-8. View

Lukanova A, Toniolo P, Akhmedkhanov A, Hunt K, Rinaldi S, Zeleniuch-Jacquotte A . A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev. 2001; 10(5):443-52. DOI: 10.1097/00008469-200110000-00008. View

Kanis J, Melton 3rd L, Christiansen C, JOHNSTON C, Khaltaev N . The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9(8):1137-41. DOI: 10.1002/jbmr.5650090802. View

10.

Zhao H, Liu J, Ning G, Zhao Y, Chen Y, Sun L . Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int. 2007; 19(2):221-6. DOI: 10.1007/s00198-007-0440-y. View

11.

Prior J, Kirkland S, Joseph L, Kreiger N, Murray T, Hanley D . Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. CMAJ. 2001; 165(8):1023-9. PMC: 81536. View

12.

Pinheiro S, Holmes M, Pollak M, Barbieri R, Hankinson S . Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2005; 14(9):2147-53. DOI: 10.1158/1055-9965.EPI-04-0944. View

13.

Horsman A, Jones M, Francis R, Nordin C . The effect of estrogen dose on postmenopausal bone loss. N Engl J Med. 1983; 309(23):1405-7. DOI: 10.1056/NEJM198312083092301. View

14.

Berenson A, Breitkopf C, Grady J, Rickert V, Thomas A . Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. 2004; 103(5 Pt 1):899-906. DOI: 10.1097/01.AOG.0000117082.49490.d5. View

15.

Rechler M . Insulin-like growth factor binding proteins. Vitam Horm. 1993; 47:1-114. DOI: 10.1016/s0083-6729(08)60444-6. View

16.

Sultana S, Choudhury S, Choudhury S . Effect of combined oral contraceptives on bone mineral density in pre and postmenopausal women. Mymensingh Med J. 2002; 11(1):12-4. View

17.

Kuohung W, Borgatta L, Stubblefield P . Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception. 2000; 61(2):77-82. DOI: 10.1016/s0010-7824(00)00086-x. View

18.

Giustina A, Mazziotti G, Canalis E . Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008; 29(5):535-59. PMC: 2726838. DOI: 10.1210/er.2007-0036. View

19.

Blackmore K, Wong J, Knight J . A cross-sectional study of different patterns of oral contraceptive use among premenopausal women and circulating IGF-1: implications for disease risk. BMC Womens Health. 2011; 11:15. PMC: 3123282. DOI: 10.1186/1472-6874-11-15. View

20.

Pasco J, Kotowicz M, Henry M, Panahi S, Seeman E, Nicholson G . Oral contraceptives and bone mineral density: A population-based study. Am J Obstet Gynecol. 2000; 182(2):265-9. DOI: 10.1016/s0002-9378(00)70209-2. View